Iron for Heart Health: What the Research Says
Overview
Iron is an essential mineral that plays a critical role in oxygen transport, energy production, and cellular function throughout the body. While iron deficiency is widely recognized for causing anemia, emerging research reveals a more nuanced relationship between iron status and cardiovascular health. For patients with heart failure or coronary artery disease, iron deficiency appears to be far more common than previously appreciated—and correcting it may offer meaningful clinical benefits.
The cardiovascular research on iron supplementation presents a compelling story: intravenous iron therapy reduces heart failure hospitalizations and cardiovascular death in carefully selected patients, while oral iron shows limited efficacy despite correcting iron blood markers. Understanding this distinction, along with the underlying mechanisms, is essential for anyone considering iron supplementation for heart health.
How Iron Affects Heart Health
Iron's impact on cardiovascular function operates through three distinct biological pathways:
1. Cardiomyocyte Energy Production
The heart is perhaps the most metabolically demanding organ in the body, requiring constant ATP (energy) production to sustain contractions. Iron is a critical component of mitochondrial electron transport chains and cytochrome enzymes—the molecular machinery responsible for generating ATP. When systemic iron stores become depleted (indicated by transferrin saturation below 15–16%), cardiomyocytes lose their intracellular iron reserves. This leads to impaired ATP production, reduced contractility, and ultimately compromised heart function.
2. Oxygen Transport and Skeletal Muscle Function
Iron forms the core of hemoglobin, the protein that transports oxygen from the lungs to tissues. Beyond this well-known role, iron also exists within skeletal muscle as myoglobin, which facilitates oxygen uptake and storage within muscle fibers. In heart failure patients, iron deficiency diminishes the heart's ability to deliver oxygen-rich blood to working muscles and reduces the muscles' capacity to utilize that oxygen. This contributes to exercise intolerance—a hallmark symptom of heart failure—independent of changes in hemoglobin levels alone.
3. Systemic Inflammation and Myocardial Damage
Iron deficiency triggers inflammatory pathways that damage the myocardium (heart muscle). Conversely, the relationship between iron and inflammation is bidirectional: excess iron can paradoxically worsen inflammation through oxidative stress and ferroptosis (iron-dependent cell death). The goal in cardiovascular disease is optimal iron status—neither deficiency nor excess—to minimize inflammation while supporting energy production.
What the Research Shows
Intravenous Iron Therapy: Robust Evidence for Heart Failure
The strongest evidence for iron supplementation in cardiovascular disease comes from intravenous iron therapy in heart failure patients. Large meta-analyses of randomized controlled trials demonstrate consistent, clinically meaningful benefits.
Hospitalizations and Mortality
A comprehensive meta-analysis of 14 randomized controlled trials involving 7,786 heart failure patients found that intravenous iron therapy reduced the composite endpoint of heart failure hospitalization or cardiovascular death by 18% (relative risk 0.82, 95% confidence interval 0.72–0.92). When examining hospitalizations alone, the reduction was even more pronounced:
- Total heart failure hospitalizations decreased by 22% (RR 0.78, 95% CI 0.66–0.91)
- Total cardiovascular hospitalizations decreased by 17% (RR 0.83, 95% CI 0.73–0.96)
These reductions represent hundreds of prevented hospitalizations across thousands of patients—substantial public health and quality-of-life benefits.
Notably, the reduction in all-cause mortality did not reach statistical significance (OR 0.93, 95% CI 0.83–1.04), suggesting that while intravenous iron prevents hospitalizations and cardiovascular events, it may not extend overall survival. This distinction is important for managing expectations about what iron therapy can achieve.
Functional Capacity
Beyond reducing hospitalizations, intravenous iron improves patients' ability to exercise. A meta-analysis measuring the 6-minute walk test—a standard assessment of functional capacity in heart failure—found that intravenous iron improved walking distance by approximately 19 meters (weighted mean difference 18.99 meters, 95% CI 7.41–30.57). While this may sound modest, such improvements correspond to meaningful gains in activities of daily living and quality of life for heart failure patients.
Specific Iron Formulations
Ferric carboxymaltose (FCM), a specific intravenous iron formulation, was evaluated in multiple high-quality trials including CONFIRM-HF, AFFIRM-AHF, and HEART-FID. The pooled analysis of these studies (4,501 participants) demonstrated that FCM reduced total cardiovascular hospitalizations by 17% (RR 0.83, 95% CI 0.73–0.96) and heart failure hospitalizations by 16% (RR 0.84, 95% CI 0.71–0.98).
Oral Iron: Disappointing Results Despite Improved Markers
In stark contrast to intravenous iron, oral iron supplementation has not demonstrated clinical benefits in heart failure patients, despite effectively raising blood iron markers.
The IRONOUT HF trial, a double-blind, placebo-controlled randomized controlled trial of 225 patients with heart failure with reduced ejection fraction (HFrEF), tested oral iron polysaccharide at 150 mg twice daily for 16 weeks. Despite successfully increasing ferritin levels and transferrin saturation, oral iron failed to improve the primary endpoint: peak oxygen consumption (VO2) during exercise testing.
This null result raises important questions about bioavailability and delivery mechanisms. While some studies suggest oral iron can achieve bioavailability comparable to intravenous iron in healthy individuals, this does not translate to clinical benefit in heart failure patients. Possible explanations include gastrointestinal absorption limitations in the setting of heart failure (which impairs splanchnic perfusion and absorption), the need for higher systemic iron concentrations than oral dosing can reliably achieve, or iron depot depletion in specific cardiac tissue compartments that oral supplementation cannot adequately replenish.